Marcus STAMINA Team appears to be a U.S.-based geroscience pilot centered on whether intermittent dasatinib plus quercetin can be feasibly given to older adults with slow gait speed and mild cognitive impairment as a senolytic strategy aimed at mobility and cognition; the strongest direct evidence is a 2023 rationale-and-design paper for a 12-week, single-arm, open-label feasibility study in 12 participants, which supports serious academic sponsorship but not efficacy.
This project is run by a public research institute. Any funding here takes the form of a grant, donation, or public contract — not equity. There is no financial return expected.The STAMINA project is run by the Hinda and Arthur Marcus Institute for Aging Research, a Harvard Medical School-affiliated gerontological research institute at Hebrew SeniorLife.
Mechanism and evidence quality
How much success could unlock
Deal-quality signals
Weighted composite
Where this project sits
Positioned against every public project across all sections
If cellular senescence contributes causally to mobility decline and cognitive impairment in older adults, then intermittent senolytic treatment with dasatinib plus quercetin may improve or help preserve gait and cognition in this high-risk population.
The project is built on the geroscience claim that senescent cells and their secretory phenotype contribute to age-related functional decline; dasatinib plus quercetin is used as a senolytic combination intended to selectively reduce senescent-cell burden rather than merely compensate for symptoms.
The concrete approach in the direct project evidence is a 12-week, single-arm, open-label, pre-post pilot in 12 adults aged 65+ with slow gait speed and mild cognitive impairment, using intermittent dasatinib plus quercetin and assessing feasibility in a mobility- and cognition-impaired aging population.
Early clinical feasibility stage. Evidence supports study rationale, design, named investigators, and institutional affiliations across Hebrew SeniorLife, Harvard-linked institutions, Tufts, and Mayo Clinic, but the provided evidence does not include outcome, safety, or controlled efficacy results.
Minimum success would be showing that this population can be recruited, retained, and dosed with intermittent dasatinib plus quercetin with acceptable tolerability and usable adherence/assessment data. Stronger success would require signal-level improvement in gait and cognitive measures, but any such claim would still need confirmation in a larger controlled trial because the described study is small, open-label, and uncontrolled.
If the central claim is validated, the next 1-3 years could support randomized follow-on trials of senolytics in older adults with early mobility and cognitive decline, more concrete geriatric use cases for senescence-targeting interventions, and practical trial programs focused on delaying functional deterioration before overt dementia or severe disability.
If this succeeds over 5-20 years, it could help establish senescence-targeting interventions as a new therapeutic class for functional aging, opening programs that treat mobility loss and cognitive decline through shared aging biology rather than disease silos alone, and could expand into combined geroscience strategies, stratified trials for pre-dementia populations, and broader prevention-oriented aging medicine.
The upside case is that STAMINA identifies a tractable, clinically meaningful geroscience intervention: clearing senescent cells could become a practical way to improve or delay age-related decline across both physical and cognitive domains in older adults before late-stage neurodegeneration, with unusually strong translational leverage because the target population and endpoints are clinically recognizable.
The downside case is that the project is overinterpreting a mechanistic aging hypothesis from weak clinical footing: the direct study evidence is only a small, single-arm feasibility design, so apparent benefits could be placebo, regression to the mean, measurement noise, or selection effects, while dasatinib plus quercetin may prove too hard to tolerate, too nonspecific, or too biologically blunt to deliver meaningful functional benefit in an older impaired population.
The direct project evidence is a rationale-and-design paper for a 12-week, single-arm, open-label feasibility study in 12 older adults, not an outcomes paper. That is enough to show a concrete clinical plan, but it leaves the core question unresolved: whether intermittent dasatinib plus quercetin produces real functional benefit in gait or cognition rather than noise, placebo effects, or regression to the mean. The Mayo-linked patent record supports that the combination is being pursued as a senolytic modality, but patents do not validate clinical efficacy.
This project is already framed in humans rather than relying only on animal work, which reduces pure animal-to-human translation risk. But the planned cohort is extremely narrow and small: older adults with both slow gait speed and mild cognitive impairment in a 12-person uncontrolled pilot. Even if the study is feasible or shows a signal, generalization across broader aging populations would remain highly uncertain.
The project is using a drug combination as a senolytic therapeutic strategy in older adults with functional impairment, which implies a conventional human-therapeutics regulatory path rather than a light-touch wellness route. The active Mayo patent family around using a src inhibitor plus a flavonoid for senescence-associated conditions suggests there may also be licensing and freedom-to-operate considerations around the exact modality.
Competitive pressure looks meaningful. The D+Q approach itself sits inside an active Mayo patent family, and the broader senolytics space shows many alternative modalities and IP positions from Mayo/Buck/Unity, Rubedo, and others. That raises the risk that this exact approach is crowded, that better-funded groups reach convincing clinical milestones first, or that the field shifts toward other senolytic strategies before this program de-risks.
Execution risk is moderate rather than extreme. The paper shows a named multi-investigator team, including authors associated with senescence and aging research, which supports credibility for running a small academic feasibility study. But the evidence still only demonstrates readiness for a 12-person pilot; it does not show that the team has already delivered clinical outcomes, scaled recruitment, or advanced the program into controlled follow-on trials.
Near-term capital needs for a 12-person feasibility study are probably manageable, but the evidence points to a long funding runway if the project is to matter. A small uncontrolled pilot would only justify larger randomized studies, and a therapeutic aging program built around a patented senolytic combination will likely need sustained clinical and IP-backed financing to progress beyond academic proof-of-concept.
The mechanistic premise is coherent for geroscience: STAMINA explicitly frames senolytics as targeting aging-related mobility and neurological impairment, and Mayo-linked patent evidence covers dasatinib-like Src inhibitor plus flavonoid senolytic combinations for senescence-associated conditions. Still, patents and rationale/design papers are weak proof of causal benefit in older adults with gait and cognitive impairment, and the evidence does not show target engagement or senescent-cell reduction in this population.
The strongest direct evidence is a 2023 rationale-and-design article in Translational Medicine of Aging, which supports that STAMINA is a real academic feasibility study, not that the intervention works. The surrounding senolytic patent landscape shows substantial prior invention activity, but patent filings do not substitute for peer-reviewed clinical efficacy, safety, or biomarker data. No fetched evidence provides completed STAMINA outcomes.
A feasibility-study design is appropriate for testing logistics and tolerability, but it is intrinsically weak for causal claims about mobility or cognition. Based on the project evidence, the work is early clinical and design-oriented rather than a randomized, blinded, adequately powered efficacy trial. Without fetched evidence of controls, preregistered endpoints, statistical power, or completed outcomes, rigor for efficacy is low.
There is evidence that senolytic strategies are being pursued by multiple groups and institutions, including Mayo, Buck, Unity, Rubedo, Peking University, and others. That supports field-level activity, but not replication of STAMINA’s specific intervention, population, endpoints, or outcomes. No fetched evidence shows independent replication or even completed own-study replication for this project.
The project is not novel at the level of senolytics or dasatinib-plus-quercetin, which appear in earlier Mayo-linked patent evidence and a broader crowded senolytic patent landscape. Its more distinctive element is the clinical geroscience application to aging-related mobility and neurological impairment, but the provided evidence supports this as an early feasibility translation rather than a fundamentally new mechanism or modality.
The project is fairly falsifiable because a clinical feasibility study can fail on recruitment, retention, dosing, tolerability, adherence, or usable mobility and cognition assessments. The therapeutic hypothesis would be further weakened if senolytic dosing produces no functional signal or unacceptable tolerability. However, because the direct evidence indicates an early feasibility/rationale design rather than a controlled efficacy trial, negative or positive functional changes would not cleanly refute or validate the central biology.
The mechanism is credible but not especially novel: the project uses an existing senolytic strategy, dasatinib plus quercetin, aimed at senescent-cell killing rather than presenting a new target class. The direct STAMINA evidence supports a geroscience feasibility study, while earlier Mayo patent evidence shows the src-inhibitor plus flavonoid senolytic concept predates this project.
No outcome evidence is provided. The strongest direct evidence is a rationale-and-design paper for STAMINA, so any effect on gait, cognition, healthspan, or lifespan is still hypothetical. Upside could be meaningful if senescent-cell clearance improves mobility and cognitive decline, but the evidence only supports testing feasibility, not efficacy.
Near-term cross-domain impact is limited because the project is an early clinical feasibility study rather than a validated platform. It does connect aging biology, mobility, cognition, neurology, and geriatric medicine, but the fetched evidence does not show current usable capabilities in adjacent fields.
If successful, the project could open larger controlled trials of senolytics for clinically recognizable functional aging endpoints, especially mobility and cognitive impairment. The broader senolytic patent landscape suggests this is part of a wider therapeutic class, but STAMINA itself remains a small feasibility step.
A first demonstrable result is plausibly near-term because the direct study design is a 12-week feasibility study. However, a persuasive clinical efficacy result would require a larger controlled trial, so the high score applies only to feasibility, not proof of healthspan benefit.
A positive result would strengthen the claim that senescence is a modifiable driver of age-related mobility and cognitive impairment, which would be important for geroscience. But because the direct evidence is an open-label feasibility design, even apparent benefit would not yet invalidate mainstream assumptions about aging, dementia, or frailty treatment.
The upside is large if senolytics can modify shared aging biology and improve both mobility and cognition in older adults. That would support a broad healthspan therapeutic thesis. The score is capped because current direct evidence is only a small, open-label feasibility design, not efficacy.
The fetched evidence shows academic authorship and institutional patent activity, but no evidence of founder capital at risk, salary sacrifice, equity exposure, or comparable personal commercial commitment. Public academic reputation is modestly at stake, but that is weaker than direct economic skin in game.
The problem area is large because the project targets age-related mobility impairment plus mild cognitive impairment, both clinically important aging phenotypes. However, the fetched evidence does not provide a market-size source, so the TAM is a benchmark estimate for a potential geroscience therapeutic addressing mobility/cognitive decline rather than a cited project-specific market figure.
Defensibility is limited for this specific project: the direct intervention is intermittent dasatinib plus quercetin, using known compounds, and the strongest relevant Mayo senolytic combination patent family includes abandoned, ceased, and active/granted filings rather than clear exclusive control by the Marcus STAMINA team. The broader senolytic patent landscape is crowded, which weakens freedom to own the category.
The project has credible academic execution capacity: the STAMINA design paper lists investigators associated with geroscience, aging, and senolytic work, including Kirkland, Tchkonia, Travison, and Lipsitz. Still, evidence supports capability to design and run a small feasibility study, not to commercialize or execute late-stage drug development.
The fetched evidence shows academic authorship and institutional patent activity, but no evidence of founder capital at risk, salary sacrifice, equity exposure, or comparable personal commercial commitment. Public academic reputation is modestly at stake, but that is weaker than direct economic skin in game.
The clearest validation is that STAMINA is designed as a clinical feasibility study in older adults, implying planned or attempted patient enrollment. There is no fetched evidence of completed outcomes, payer/pharma demand, LOIs, options, regulatory designations, or paying customers.
Using repurposed small molecules should be more capital efficient than novel preclinical biotech, but clinical proof in aging-related mobility/cognition would likely require randomized Phase 2 and potentially large outcomes-oriented trials. Estimate $120M to self-sustaining or strategic-exit readiness, below a fully novel drug program but still substantial.
A near-term value inflection could come from feasibility or early randomized clinical readouts rather than revenue. Because the direct evidence is only a 12-week feasibility-study design, a meaningful controlled readout likely requires a follow-on trial; estimate 36 months to a value-relevant clinical signal.
The regulatory route is unclear because aging, mobility decline, and mild cognitive impairment are not a simple established drug-approval indication for senolytics. Repurposed dasatinib has known regulatory precedent in other uses, but the evidence here does not show FDA alignment, validated endpoints, or a designated pathway.
Competitive freedom is weak. The fetched patent set shows many organizations pursuing senolytic or senescence-modulating approaches, including Mayo, Unity, Rubedo, Buck, Gero, Insilico, Stanford-linked work, and others. STAMINA may be differentiated clinically by its mobility-plus-cognition feasibility population, but the therapeutic concept itself is not uncrowded.
The upside is large if senolytics can modify shared aging biology and improve both mobility and cognition in older adults. That would support a broad healthspan therapeutic thesis. The score is capped because current direct evidence is only a small, open-label feasibility design, not efficacy.
No fetched evidence provides M&A, licensing, option, or comparable exit transactions for senolytics or geroscience therapeutics. The presence of multiple patenting organizations suggests strategic interest in the field, but that is not the same as a demonstrated exit market.
Commercialization would likely require standard clinical-development spend despite low molecule-discovery cost, because the target population is older and clinically heterogeneous and efficacy endpoints would need controlled validation. Estimate $180M to first marketed product, lower than a novel biologic platform but still high for an aging indication.
Cellular senescence contributes causally to age-related declines in muscle, cognitive, and immune function. Senolytic strategies should improve healthspan by selectively reducing the harmful effects of senescent cells, thereby lowering senescence-associated damage or dysfunction that accumulates with age. Testable predictions include: older adults receiving an effective senolytic intervention should show reduced markers of cellular senescence or senescence-associated secretory activity; reductions in senescence burden should correlate with improvements or slower decline in muscle function, cognitive performance, and immune function; and individuals or tissues with higher baseline senescence burden should show greater benefit from senolytic treatment.
The core premise is biologically credible: senescent cells can accumulate with age, secrete inflammatory and tissue-remodeling factors, and plausibly contribute to dysfunction across multiple systems. The theory is internally coherent because senolytic benefit follows logically if senescent cells are causally harmful. However, the premise is broad, and the provided evidence context does not include direct publication support for muscle, cognitive, and immune outcomes in older adults.
The theory offers a unified explanation for age-related decline across muscle, cognition, and immune function through a shared causal burden of senescent cells and their secretory activity. This gives it meaningful explanatory reach. Still, the provided context does not show that it explains observed human evidence better than alternatives such as chronic inflammation, mitochondrial dysfunction, stem-cell exhaustion, vascular pathology, proteostasis failure, or immune remodeling.
The theory is strongly testable. It makes concrete predictions about biomarker reduction after senolytic treatment, correlations between reduced senescence burden and functional outcomes, and greater benefit among individuals or tissues with higher baseline senescence. It could be weakened or falsified if effective senolytics reliably reduce senescence markers without improving relevant functions, or if baseline senescence burden fails to predict benefit.
The theory addresses a central and difficult problem in aging biology: whether a cellular damage state can causally drive broad healthspan decline and whether removing that burden can improve multiple functional systems. Its ambition is high because it proposes a tractable intervention against a cross-cutting aging mechanism, though it is not wholly novel within geroscience because senescence and senolytics are already established research programs.
The core premise is biologically credible: senescent cells can accumulate with age, secrete inflammatory and tissue-remodeling factors, and plausibly contribute to dysfunction across multiple systems. The theory is internally coherent because senolytic benefit follows logically if senescent cells are causally harmful. However, the premise is broad, and the provided evidence context does not include direct publication support for muscle, cognitive, and immune outcomes in older adults.
The theory offers a unified explanation for age-related decline across muscle, cognition, and immune function through a shared causal burden of senescent cells and their secretory activity. This gives it meaningful explanatory reach. Still, the provided context does not show that it explains observed human evidence better than alternatives such as chronic inflammation, mitochondrial dysfunction, stem-cell exhaustion, vascular pathology, proteostasis failure, or immune remodeling.
The theory is strongly testable. It makes concrete predictions about biomarker reduction after senolytic treatment, correlations between reduced senescence burden and functional outcomes, and greater benefit among individuals or tissues with higher baseline senescence. It could be weakened or falsified if effective senolytics reliably reduce senescence markers without improving relevant functions, or if baseline senescence burden fails to predict benefit.
The theory addresses a central and difficult problem in aging biology: whether a cellular damage state can causally drive broad healthspan decline and whether removing that burden can improve multiple functional systems. Its ambition is high because it proposes a tractable intervention against a cross-cutting aging mechanism, though it is not wholly novel within geroscience because senescence and senolytics are already established research programs.
★ AI estimate from available evidence — click any star for rationale.